Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?

References

• Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213. doi:10.1186/ar309720735863
   PubMed Web of Science ®Google Scholar
• Turesson C, O’Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62(8):722–727. doi:10.1136/ard.62.8.72212860726
   PubMed Web of Science ®Google Scholar
• Raimundo K, Solomon JJ, Olson AL, et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46(4):360–369.
   PubMed Web of Science ®Google Scholar
• Wells AU, Denton CP. Interstitial lung disease in connective tissue disease–mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–739. doi:10.1038/nrrheum.2014.14925266451
   PubMed Web of Science ®Google Scholar
• Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–626. doi:10.1016/j.semarthrit.2013.09.00524231065
   PubMed Web of Science ®Google Scholar
• Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford). 2002;41(3):262–267. doi:10.1093/rheumatology/41.3.26211934961
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Alexandrakis MG, Siafakas NM, et al. Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):91–104.16053024
   PubMed Web of Science ®Google Scholar
• Kahler CM, Heininger P, Loeffler-Ragg J, et al. Infliximab therapy in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2007;176(4):417; author reply 417–418.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-alpha therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013;22(4):394–402. doi:10.1002/pds.340923359391
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4(8):e005615. doi:10.1136/bmjopen-2014-005615
   PubMed Web of Science ®Google Scholar
• Nakashita T, Ando K, Takahashi K, Motojima S. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016;54(5):376–379. doi:10.1016/j.resinv.2016.03.001
   PubMed Web of Science ®Google Scholar
• Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. doi:10.1186/s13075-015-0835-726555431
   PubMed Web of Science ®Google Scholar
• Koo BS, Hong S, Kim YJ, et al. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med. 2015;30(1):104–109. doi:10.3904/kjim.2015.30.1.10425589842
   PubMed Web of Science ®Google Scholar
• Druce KL, Iqbal K, Watson KD, et al. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open. 2017;3(1):e000473. doi:10.1136/rmdopen-2016-00039128955489
   PubMed Web of Science ®Google Scholar
• Detorakis EE, Magkanas E, Lasithiotaki I, et al. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-alpha agents. Clin Exp Rheumatol. 2017;35(1):43–52.
   PubMed Web of Science ®Google Scholar
• Cortet B, Perez T, Roux N, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(10):596–600. doi:10.1136/ard.56.10.5969389220
   PubMed Web of Science ®Google Scholar
• Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2017;29(3):254–259. doi:10.1097/BOR.000000000000038028207496
   PubMed Web of Science ®Google Scholar
• Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17(5):362–367. doi:10.1097/MCP.0b013e3283483ea521597375
   PubMed Web of Science ®Google Scholar
• Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004;24(4):708. doi:10.1183/09031936.04.00076904
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25(1):23–28.17417986
   PubMed Web of Science ®Google Scholar
• Ostor AJ, Crisp AJ, Somerville MF, Scott DGI. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ (Clinical Research Ed). 2004;329(7477):1266. doi:10.1136/bmj.329.7477.1266
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256–264. doi:10.1016/j.semarthrit.2010.11.00221277618
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498–508. doi:10.3109/s10165-011-0541-521993918
   PubMed Web of Science ®Google Scholar
• Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single center. Rheumatology (Oxford) 2017;56(8):1348–1357.
   Google Scholar
• Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397–1405. doi:10.1378/chest.09-044419892679
   PubMed Web of Science ®Google Scholar
• Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33(3):622–628.16511933
   PubMed Web of Science ®Google Scholar
• Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33(6):1189–1193.16622902
   PubMed Web of Science ®Google Scholar
• Bedrossian CW, Sussman J, Conklin RH, et al. Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol. 1984;82(2):148–154. doi:10.1093/ajcp/82.2.1486380265
   PubMed Web of Science ®Google Scholar
• Alaee S, Jones Q. Case of drug-induced interstitial lung disease secondary to adalimumab. BMJ Case Rep. 2018;pii:bcr-2018-224375.
   PubMedGoogle Scholar
• Migita K, Tsuji Y, Hisatomi K, et al. Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol. Modern Rheumatology. 2017;27(6):1079–1082. doi:10.3109/14397595.2015.105900826044288
   PubMed Web of Science ®Google Scholar
• Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002;122(5):1858–1860.
   Google Scholar
• Vassallo R, Matteson E, Thomas CF, Jr. Clinical Response of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis factor-alpha Inhibition. Chest. 2002;122(3):1093–1096.12226061
   PubMedGoogle Scholar
• Chatterjee, S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33(4):276–277.15370726
   PubMed Web of Science ®Google Scholar
• Hennum J, Nace J, Shammash E, Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis. J Rheumatol. 2006;33(9):1917–1918.16960963
   PubMed Web of Science ®Google Scholar
• Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol. 2006;16(4):251–255.16906378
   PubMedGoogle Scholar
• Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford). 2006;45(8):1048–1049.16760195
   PubMed Web of Science ®Google Scholar
• Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006;55(1):157–159.
   PubMed Web of Science ®Google Scholar
• Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford). 2006;45(10):1312–1313.16935921
   PubMed Web of Science ®Google Scholar
• Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003;49(4):617; 617–618.
   Google Scholar
• Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151–1154.
   Google Scholar
• Tournadre A, Ledoux-Eberst J, Poujol D, Dubost JJ, Ristori JM, Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: Two cases. Joint Bone Spine. 2008;75(2):215–218.17977770
   PubMed Web of Science ®Google Scholar
• Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009;30(2):275–276.19373466
   PubMed Web of Science ®Google Scholar
• Pearce F, Johnson SR, Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford). 2012;51(3):578–580.22116998
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol. 2010;20(5):518–521.20467775
   PubMed Web of Science ®Google Scholar
• Komiya K, Ishii H, Fujita N, et al. Adalimumab-induced interstitial pneumonia with an improvement of pre-existing rheumatoid arthritis-associated lung involvement. Intern Med. 2011;50(7):749–751.21467710
   PubMed Web of Science ®Google Scholar
• Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol Int. 2012;32(4):1055–1057.
   Google Scholar
• Millar A, McKew J, Taggart A. Fatal fibrosing alveolitis with certolizumab. Rheumatology (Oxford). 2012;51(5):953–955.22328567
   PubMed Web of Science ®Google Scholar
• Lager J, Hilberg O, Lokke A, Bendstrup E. Severe interstitial lung disease following treatment with certolizumab pegol: a case report. European respiratory review: an official journal of the European Respiratory Society. 2013;22(129):414–416.23997067
   PubMedGoogle Scholar
• Glaspole IN, Hoy RF, Ryan PF. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(12):2302–2304.
   Google Scholar
• Dias OM, Pereira DA, Baldi BG, et al. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2014;40(1):77–81.24626274
   PubMed Web of Science ®Google Scholar
• Watad A, Perelman M, Mansour R, Shoenfeld Y, Amital H. Etanercept-Induced Pneumonitis: Severe Complication of Tumor Necrosis Factor-Alpha Blocker Treatment. The Israel Medical Association journal: IMAJ. 2015;17(2):130–132.26223096
   PubMed Web of Science ®Google Scholar